EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , 

 ISSN 2394-3211

Impact Factor: 6.222

 ICV - 79.57

Abstract

EFFICACY AND SAFETY OF FIXED DOSE COMBINATIONS (FDC’S) OF TAMSULOSIN AND SILODOSIN WITH DUTASTERIDE IN PATIENTS OF LOWER URINARY TRACT SYMPTOMS (LUTS) WITH BENIGN PROSTATIC HYPERPLASIA (BPH): A RANDOMISED CLINICAL STUDY

M. C. Gupta, Nishant Madan* and Hemant Kamal

ABSTRACT

Background: α-1 blockers, which improves dynamic component, and 5α-reductase inhibitors (5ARIs), which halt the progression of disease, have been rationally used as FDC’s in patients of LUTS with BPH. This study compared efficacy and safety of FDC’s of tamsulosin and silodosin with dutasteride. Methods: Sixty-four patients were randomized to receive once daily FDC’s of tamsulosin with dutasteride (Group 1) and silodosin with dutasteride (Group 2) over 16 weeks. Primary efficacy outcome measures were change in International prostate symptom score (IPSS) and uroflowmetry parameters. Secondary efficacy outcome measures were change in prostatic and post-void residual urine volume determined ultrasonographically. Safety was evaluated by using standard adverse drug reaction (ADR) reporting form of CDSCO. Results: IPSS improved in both group 1 and 2 by 48.6% and 49.13% respectively at 16 weeks (p <0.001). Maximum urinary flow rate (Qmax) improved by 2.42 ml/sec & 2.27 ml/sec in group 1 and 2 respectively at 16 weeks (p value <0.001). Other uroflowmetry parameter also improved significantly in both the groups equally except time to maximum flow (TQmax) which was better with tamsulosin combination. Prostate volume reduced significantly by 13.18% and 10.96% and post-void residual urine volume reduced significantly by 58.49% and 54.27% in group 1 and 2 respectively. Both FDCs had a comparable ADR profile mainly retrograde ejaculation and dizziness. Conclusion: FDC’s of tamsulosin and silodosin with dutasteride are equally effective and safe medical therapy for LUTS with BPH and can be used as per physician preference.

Keywords: Tamsulosin, Silodosin, Dutasteride, Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia.


[Full Text Article]

INDEXING

NEWS & UPDATION

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 September 2021 Issue has been Published, Kindly check it on http://www.ejpmr.com/home/current_issues

  • EJPMR: SEPTEMBER ISSUE PUBLISHED

    SEPTEMBER Issue has been successfully launched on 1 September 2021.

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from  5.804 to 6.222, due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI )